Advertisement
Research ArticleArticle

Allosteric Activation of the Ca2+ Receptor Expressed in Xenopus laevis Oocytes by NPS 467 or NPS 568

Lance G. Hammerland, James E. Garrett, Benjamin C. P. Hung, Cynthia Levinthal and Edward F. Nemeth
Molecular Pharmacology June 1998, 53 (6) 1083-1088;

Abstract

The Ca2+ receptor is a G protein-coupled receptor that enables parathyroid cells and certain other cells in the body to respond to changes in the concentration of extracellular Ca2+. In this study, two novel phenylalkylamine compounds, NPS 467 and NPS 568, were examined for effects on Xenopus laevis oocytes expressing the bovine or human parathyroid Ca2+ receptors. Increases in chloride current (ICl) were elicited in oocytes expressing the bovine Ca2+ receptor when the extracellular Ca2+concentration was raised above 1.5 mm, whereas Ca2+ concentrations > 3 mm were generally necessary to elicit responses in oocytes expressing the human Ca2+ receptor. NPS 467 and NPS 568 potentiated the activation of ICl by extracellular Ca2+ in oocytes expressing either Ca2+ receptor homolog, and this resulted in a leftward shift of the Ca2+concentration-response curve. Neither compound was active in the absence of extracellular Ca2+. Certain inorganic and organic cations known to activate the Ca2+ receptor were substituted for elevated levels of extracellular Ca2+ to increase ICl and the effects of these agonists were also potentiated by NPS 568 or NPS 467. The effects of NPS 568 were stereoselective and the R-enantiomer was about 10-fold more potent than the corresponding S-enantiomer. Neither NPS 467 nor 568 affected ICl in water-injected oocytes or in oocytes expressing the substance K receptor or the metabotropic glutamate receptor 1a. These results provide compelling evidence that NPS 467 and NPS 568 act directly upon the parathyroid Ca2+receptor to increase its sensitivity to activation by extracellular Ca2+. This activity suggests that these compounds are positive allosteric modulators of the Ca2+ receptor. As such, these compounds define a new class of pharmacological agents with potent and selective actions on the Ca2+ receptor.

The Ca2+ receptor is a cell surface G protein-coupled receptor that enables parathyroid cells and certain other cells in the body to respond to small changes in the concentration of extracellular Ca2+ (Brown et al., 1995; Nemeth, 1996). In parathyroid cells, the Ca2+ receptor monitors changes in the level of serum Ca2+ and is coupled to the regulation of PTH secretion. Activation of the parathyroid Ca2+ receptor by increased levels of extracellular Ca2+ results in the rapid formation of inositol 1,4,5-trisphosphate, the mobilization of intracellular Ca2+, and the inhibition of PTH secretion (Brown, 1991). This reciprocal relationship between extracellular Ca2+ levels and PTH secretion is largely responsible for maintaining systemic Ca2+homeostasis. Because of its central role in this homeostatic mechanism, the Ca2+ receptor is a promising molecular target for drugs designed to alter circulating levels of PTH. At present, however, no potent and selective compounds are known to act at this novel receptor.

The Ca2+ receptor responds not only to extracellular Ca2+, but also to a variety of inorganic and organic cations, such as Mg2+, La3+, spermine, and neomycin (Nemeth and Scarpa, 1987; Brown et al., 1991a, 1991b). Although some of the organic cations, such as polylysine, activate the Ca2+ receptor at nanomolar concentrations, neither the inorganic nor the organic cations possess desirable pharmaceutical properties. We have synthesized a series of phenylalkylamine compounds, typified by NPS 467 and NPS 568 (Fig.1), that mobilize intracellular Ca2+ and inhibit PTH secretion from bovine or human parathyroid cells in vitro (Steffey et al., 1993). These effects are similar to those obtained by increasing the concentration of extracellular Ca2+. To determine if these compounds act directly on the Ca2+receptor, we have expressed the bovine or human parathyroid Ca2+ receptor in Xenopus laevisoocytes and have assessed the effects of NPS 467 and NPS 568 on Ca2+-activated Cl−currents. The results provide evidence that these phenylalkylamine compounds act to potentiate the effects of cationic agonists of the Ca2+ receptor, but do so differently than all other known agonists of this receptor. The results suggest that NPS 467 and NPS 568 behave as positive allosteric modulators to increase the sensitivity of the Ca2+ receptor to extracellular Ca2+.

Figure 1
Figure 1

The chemical structures of NPS 467 (A) and NPS 568 (B), shown as the R-enantromers.

Materials and Methods

Preparation of cRNA.

The plasmid cDNA clones used were BoPCaR (Brown et al., 1993), hPCaR 4.0 (Garrett et al., 1995), bovine SKR (Nakanishi, 1991), and mGluR1a isolated from rat olfactory bulb cDNA (Masu et al., 1991). Plasmid DNA was linearized by NotI digestion, and used as template for transcription of sense-strand cRNA using T7 RNA polymerase. Transcription reactions were done as previously described (Garrettet al., 1995).

Oocyte isolation and cRNA injection.

Adult female X. laevis toads were anesthetized in 0.1% tricaine according to an animal use protocol approved by the Institutional Animal Use and Care Committee of NPS Pharmaceuticals in accordance with federal animal welfare regulations. Pieces of ovarian lobe were surgically removed and incubated for 30–60 min in Ca2+-free MBS containing 1.5 mg/ml Collagenase P (Boehringer Mannheim, Indianapolis, IN). The MBS contained 88 mm NaCl, 1 mm KCl, 0.82 mm MgSO4, 10 mm HEPES, and 2.4 mmNaCO3, pH value 7.5. Stage V or VI oocytes were separated manually and washed with MBS containing 0.8 mmCaCl2 before injection. The cRNAs of Ca2+ receptors, mGluR1a and SKR cRNAs were dissolved in water and 50 nl (12.5 ng/oocyte) of the RNA solution was injected into individual oocytes. Control oocytes were injected with water. After injection, oocytes were incubated at 16° in MBS containing 0.5 mm CaCl2 for 2–7 days before electrophysiological recording (Goldin, 1992).

Two-electrode voltage-clamp.

Voltage-recording and current-passing electrodes were filled with 3 m KCl and had resistances of 0.5–2 MΩ. Oocytes were voltage-clamped at a holding potential of −60 mV with an Axoclamp 2A amplifier (Axon Instruments, Foster City, CA) by using standard two-electrode voltage-clamp techniques (Stuhmer, 1992). Currents were recorded on a chart recorder. The standard control buffer was MBS containing 0.3 mmCaCl2 and 0.8 mmMgCl2, except where otherwise noted, and all concentrations shown are final. The 0 Ca2+solutions contained no added Ca2+, and no chelating agents were used. Test substances were applied by superfusion at a flow rate of about 5 ml/min. All experiments were done at room temperature. The activity of NPS 568 and NPS 467 was determined by their effects on agonist-evoked increases in the amplitude of ICl. Activation of ICl was quantified by measuring the peak inward current stimulated by agonist or drug, relative to the holding current at −60 mV.

Concentration-response study of agonist-mediated increases in ICl.

When multiple agonist concentrations were applied to the same oocyte, the maximal increase in ICl amplitude varied considerably among different oocytes. The same degree of variability was observed in oocytes expressing BoPCaR or hPCaR and is characteristic of the oocyte expression system. Therefore, the data for each oocyte were normalized to the maximum value obtained for each series of applications. A curve was fit to the data for each experiment with the Levenberg-Marquardt algorithm using the Kaleidograph fitting program (Synergy Software, Reading, PA). The curve for each set of data was fit to the equation ICl = A / [1 + ( EC50/ [ agonist])nH] , where A represents the dynamic range for the stimulation of ICl and nH is the Hill coefficient. The fitted value of the dynamic range was then used to calculate the percent of maximum response to agonists. All results expressed as percent of maximum response were pooled and fit to the equation: % of maximal response = 100 / [1 + (EC50 / [ agonist])nH].

Results

In oocytes injected with cRNA encoding BoPCaR, increasing the concentration of extracellular Ca2+ to levels >1.5 mm activated an inward current. The reversal potential of this current was −33 ± 3 mV (n = 4). This reversal potential corresponds well with the equilibrium potential for Cl−in this system (Goldin, 1992) and indicates that the channels activated by extracellular Ca2+ in oocytes injected with cRNA encoding BoPCaR are the endogenous Ca2+-dependent Cl− channels. These Ca2+receptor-mediated increases in ICl were transient and concentration-dependent (Fig. 2). In contrast, water-injected oocytes did not respond to application of Ca2+ in quantities up to 20 mm (data not shown). Concentration-response characteristics of BoPCaR were determined by exposing oocytes to 1, 1.7, 3, 5.6, and 10 mmextracellular Ca2+ in a cumulative manner. Oocytes expressing hPCaR 4.0 typically responded only to extracellular Ca2+ concentrations >3 mm. These oocytes were therefore exposed to 1.7, 3, 5.6, 10, and 15 mm Ca2+ for concentration-response analysis. The results of concentration-response analysis for both BoPCaR and hPCaR are shown in Fig. 3 and indicate that the bovine receptor may be somewhat more sensitive to extracellular Ca2+ than the human homolog when studied in this heterologous expression system.

Figure 2
Figure 2

Concentration-dependent increases in ICl amplitude evoked by extracellular Ca2+ inX. laevis oocytes injected 2–4 days before assay with cRNA encoding A, BoPCaR, or B, hPCaR 4.0. Tracings show IClrecorded at a holding potential of −60 mV. Oocytes were bathed in MBS containing 0.3 mm CaCl2 and exposed to higher levels of Ca2+ for the periods indicated byhorizontal bars above current tracings.

Figure 3
Figure 3

Concentration-response characteristics of BoPCaR and hPCaR. Data shown are the normalized mean IClamplitude ± standard error for 16 and 5 oocytes, respectively.

The activation of ICl by elevated concentrations of extracellular Ca2+ was potentiated in the presence of 1 μm NPS R-568 (Fig.4). In contrast, noninjected oocytes did not respond to NPS R-467 or NPS R-568 at concentrations up to 100 μm, in either the absence or the presence of added Ca2+ (not shown). However, when extracellular Ca2+ was omitted, the stimulatory activity of NPS R-467 and NPS R-568 was abolished (Fig.5). Oocytes expressing hPCaR 4.0 also responded to application of extracellular Ca2+and these responses were also potentiated by NPS R-568. These results suggest that NPS R-568 may act by sensitizing Ca2+ receptors to activation by extracellular Ca2+. The effects of NPS R-467 and of NPS R-568 on the Ca2+ concentration-response relationship were determined in oocytes expressing BoPCaR in the presence of NPS R-467 or R-568 at concentrations of 1 μm, 3 μm, or 10 μm (Fig.6A). Either compound caused a dose-dependent, leftward shift in the Ca2+concentration-response curve. In oocytes expressing hPCaR 4.0, the effect of elevated extracellular Ca2+ was determined in the presence of 3 μm NPS R-568 and this also resulted in a leftward shift in the Ca2+concentration-response curve (Fig. 6B).

Figure 4
Figure 4

NPS R-568 potentiation of Ca2+receptor-dependent activation of ICl in oocyte injected with A, hPCaR 4.0, or B, BoPCaR cRNA 2–4 days earlier. Horizontal bars indicate the duration of substance application. Extracellular Ca2+ concentration was increased transiently to 3 mm or 5.6 mm and then, after washout, 3 mm or 5.6 mm calcium was applied in the presence of 1 μm or 3 μm NPS R-568.

Figure 5
Figure 5

Ca2+ receptor-mediated increase in ICl by NPS R-568 requires the presence of extracellular Ca2+. Tracing shows current recorded at a holding potential of −60 mV in an X. laevis oocyte injected with BoPCaR 4 days before assay. Dotted horizontal bar, duration of 1 mm Ca2+ application; bold solid bar, period during which Ca2+ was removed;plain solid bar, period when 1 μm NPS R-568 was present.

Figure 6
Figure 6

A, Concentration-response curves for Ca2+ alone (□) and for Ca2+ plus 1 μm (▴), 3 μm (•), and 10 μm (♦) NPS R-568 and 10 μm NPS R-467 (▪) in oocytes that were injected at least 2 days earlier with BoPCaR cRNA. Data shown are the mean ICl amplitude ± standard error (n = 16, 5, 5, 4, and 4 for each concentration, respectively). EC50 values in millimolar for Ca2+, Ca2+ plus 1 μm NPS R-568, Ca2+ plus 3 μm NPS R-568, and Ca2+ plus 10 μm NPS R-568 were 5.1 ± 0.1, 3.6 ± 0.2, 3.2 ± 0.1, and 1.5 ± 0.1, respectively. Hill coefficients for Ca2+, Ca2+plus 1 μm NPS R-568, Ca2+ plus 3 μm NPS R-568, and Ca2+ plus 10 μm NPS R-568 were 4.5 ± 0.3, 3.3 ± 0.5, 2.3 ± 0.1, and 3.4 ± 0.7, respectively. B, Concentration-response curve for Ca2+ alone and for Ca2+ plus 3 μm NPS R-568 in oocytes expressing hPCaR 4.0. EC50 values in millimolar for Ca2+ and Ca2+ plus 3 μm NPS R-568 were 7.6 ± 1.7 and 3.2 ± 0.2 with Hill coefficients of 3.6 ± 0.2 and 5.4 ± 1.7, respectively.

The stereoselectivity in the activation of ICl by NPS 568 (which contains a single chiral carbon, Fig. 1) was examined inX. laevis oocytes expressing BoPCaR. Extracellular Ca2+ (3 mm) was applied alone, then in the presence of various concentrations of NPS S-568. After washout, Ca2+ was reapplied together with NPS R-568 and the response amplitudes were compared. Application of NPS R-568 (1 μm) greatly enhanced the response to extracellular Ca2+, but NPS S-568 was effective only at augmenting responses at concentrations ≥3 μm. Overall, the potentiation of Ca2+ responses by 10 μm NPS S-568 was slightly less than that evoked by 1 μm NPS R-568 (Fig. 7). When 10 μm NPS S-568 was coapplied with 3 mmCa2+, responses were increased by 150 ± 42% (n = 3) over responses to 3 mmCa2+ alone, whereas 1 μm NPS R-568 increased the response to 3 mm Ca2+alone by 235 ± 67% (n = 3).

Figure 7
Figure 7

NPS R-568 is a more potent activator than NPS S-568 of Ca2+ receptor-mediated increases in IClamplitude. In this representative trace the oocyte was injected with BoPCaR cRNA 3 days before assay. Horizontal bars above tracing, substances tested and duration of their application.

The parathyroid Ca2+ receptor can also be activated by elevated concentrations of certain other inorganic cations, such as Mg2+ and Gd3+, as well as organic polycations such as neomycin and spermine (Brown, 1991; Brown et al., 1991a). To determine whether NPS R-568 potentiated Ca2+receptor activation evoked by other cation agonists, the effects of NPS R-568 were examined on Ca2+ receptor-mediated responses to Mg2+, Gd3+, or neomycin in oocytes injected with BoPCaR or hPCaR 4.0 cRNA. Oocytes expressing BoPCaR were responsive to application of 10 mmMg2+, but a lower concentration (4 mmMg2+) did not increase ICl, nor did the same oocytes respond when challenged with a Ca2+-free saline that contained 10 μm NPS R-467. However, all five oocytes tested responded when challenged with 4 mm Mg2+ plus 10 μm NPS R-467. (Fig. 8A). Gadolinium-evoked responses were also potentiated by NPS R-568 in oocytes expressing BoPCaR and hPCaR 4.0 (Fig. 8B). In the absence of added Ca2+, 30 μm neomycin evoked increases in ICl in all four cells tested, whereas the application of 5 μm neomycin did not elicit a response in any of the four oocytes. However, when 5 μmneomycin was applied together with 1 μm NPS R-568, all cells responded with large increases in ICl (Fig.8C).

Figure 8
Figure 8

A, Effects of NPS R-568 on Mg2+-evoked increases in ICl. Tracing shows ICl amplitude at a holding potential of −60 mV in an X. laevis oocyte injected with BoPCaR cRNA 4 days earlier. Shown are changes in the concentration of Mg2+ in the absence of added Ca2+ and with the addition of NPS R-568 (bars above tracing). B, Effects of NPS R-467 on Gd3+-evoked increases in ICl in oocytes injected with BoPCaR. In oocytes expressing hPCaR 4.0, the response to Gd3+ is also potentiated by NPS R-568. C. Effects of NPS R-568 on neomycin-evoked increases in ICl in the absence of extracellular Ca2+.

The receptor specificity of NPS R-568 was examined in oocytes injected with cRNA encoding bovine SKR or rat mGluR1a. The SKR, the mGluR1a, and the Ca2+ receptor are coupled to inositol triphosphate-mediated Ca2+ mobilization and, therefore, produce qualitatively similar responses (increases in ICl amplitude) when these receptors are activated by their cognate ligand (Masu et al., 1991; Nakanishi, 1991;Brown et al., 1993; Garrett et al., 1995). Further, the Ca2+ receptor and mGluRs share limited sequence homology (Masu et al., 1991; Brown et al., 1993; Garrett et al., 1995). Oocytes expressing SKR did not respond to 10 μm NPS 568 either alone or when added in the presence of 10 mm Ca2+(n = 5). In those oocytes expressing the SKR, increases in ICl were evoked in response to substance K concentrations ranging from 0.3 to 10 nm and those responses were unaffected by NPS R-568 (10 μm). Further, the sensitivity of mGluR1a to activation by l-glutamate was not affected by NPS R-467. Responses to 3 μml-glutamate approximated those to 3 μml-glutamate plus 10 μm NPS R-467. (Fig.9).

Figure 9
Figure 9

Elevated Ca2+ and NPS 467 or NPS 568 do not affect SKR or mGluR1a expressed in X. laevisoocytes. A, Tracing shows the application of 10 mmCa2+ and of 10 mm Ca2+ in the presence of NPS 568 to an oocyte injected 3 days earlier with cRNA encoding the SKR. After washout of Ca2+ and NPS 568, substance K is applied. B. Tracing shows mGluR1a responses to 3 μml-glutamate, alone and in the presence of 10 μm NPS R-467, and to 30 μml-glutamate for comparison. The breaks in the mGluR1a tracings represent 7 minutes. Horizontal bars, duration of substance application.

Discussion

Expression of G protein-coupled receptors in heterologous cellular systems like X. laevis oocytes has been used to obtain evidence for direct actions of compounds on receptors and to further define their molecular pharmacology (Barnard and Bilbe, 1987). TheX. laevis oocyte system is particularly useful for exploring the pharmacology of receptors that couple through phospholipase C to the mobilization of intracellular Ca2+ because increases in the concentration of cytoplasmic Ca2+ are readily assessed by measuring currents through the Ca2+-activated chloride channels (Jiet al., 1991; Feng et al., 1996). In the present series of experiments, this system has been used to define the mechanism of action of a novel class of compounds believed to act on the Ca2+ receptor.

The present study has confirmed the results obtained with extracellular Ca2+ using the cloned bovine parathyroid Ca2+ receptor and has now included the human Ca2+ receptor, which shows some differences in sensitivity to extracellular Ca2+ (Brown et al., 1993). Comparison of the extracellular Ca2+ concentration-response curves for BoPCaR and for hPCaR 4.0 suggests that the bovine parathyroid receptor is more sensitive to Ca2+ than is the human receptor, although maximal responses of each receptor were similar. These differences in sensitivity to extracellular Ca2+are not understood, but may be related to the fidelity of expression or to species differences. The bovine and human Ca2+receptors differ in 74 of 1078 amino acids (93% identity) and 43 of these differences are found in the cytoplasmic tail region containing amino acids 920 through 1078. The other differences are distributed throughout the remainder of the protein and many of these are conservative amino acid substitutions (Brown et al., 1993;Garrett et al., 1995). One possibility is that the clustering of differences within the carboxyl-terminal region (amino acids 920-1078) may account for the differences in sensitivity to agonists in this system. The mGluR1a, which shares significant homology with the Ca2+ receptor, exists in at least three alternative splice variants that differ in the length and sequence of the carboxyl-terminal tail. Pharmacological analysis of these splice variants has showed that although the rank order of potencies of agonists is identical for all three variants, agonists are consistently more potent on the mGluR1a than on the mGluR1b and the mGluR1c (Floret al., 1996). It may be that those differences in the carboxyl-terminal tail between the human and bovine Ca2+ receptors, which are unlikely to have direct effects on agonist binding, do affect the overall sensitivity of the receptor to agonist stimulation.

The ability of NPS R-467 and NPS R-568 to elicit responses in oocytes injected with cRNA encoding the Ca2+ receptor, but not in noninjected or water-injected oocytes, provides compelling evidence that these compounds act directly on the Ca2+ receptor. The response in oocytes injected with the Ca2+ receptor cRNA does not result simply from expression of an exogenous G protein-coupled receptor because oocytes injected with substance K receptor cRNA or mGluR1a cRNA do not respond to either compound, but readily respond to their respective ligands. Although an indirect action of these compounds is possible, it would have to result from the interactions of a molecule endogenous to the oocyte that displays no similar activity on other G protein-coupled receptors. Further, the effect of these compounds is stereoselective, as it is in authentic bovine or human parathyroid cells (Steffey et al., 1993). In the aggregate then, the results offer strong evidence for an action of these compounds on the Ca2+ receptor.

Compounds that directly activate the Ca2+receptor are called “calcimimetics.” Polycations like spermine and neomycin are calcimimetics that activate the Ca2+receptor in the absence of extracellular Ca2+, whether expressed in X. laevis oocytes or in authentic parathyroid cells (Brown et al., 1991a). Compounds like NPS 467 and NPS 568, however, fail to elicit responses in the absence of extracellular Ca2+. Rather, they potentiate responses to extracellular Ca2+ as well as to other extracellular di- or trivalent cations known to act on the Ca2+ receptor. In each case, NPS 467 and NPS 568 shift the concentration-response curve for extracellular Ca2+ to the left. The most parsimonious explanation for these effects is that these phenylalkylamine compounds behave as positive allosteric modulators to increase the sensitivity of the Ca2+ receptor to activation by extracellular Ca2+. Our recent findings that extracellular Ca2+ acts in the extracellular domain (Hammerlandet al., 1995), whereas these compounds act in the transmembrane region of the Ca2+ receptor (Hammerland et al., 1996), are consistent with this mechanism of action. However, it remains uncertain if the phenylalkylamine compounds bind to the receptor in the absence of extracellular Ca2+ or if the binding of Ca2+ unmasks a cryptic binding site for these compounds. In either case, it is clear that their action is dependent on extracellular Ca2+ and that they potentiate responses to physiological and other Ca2+receptor ligands.

Calcimimetic compounds therefore include compounds that mimic or potentiate the actions of extracellular Ca2+ by acting directly on the Ca2+ receptor. We can thus describe calcimimetics as being either Type I or Type II. Type I calcimimetics act in the absence of extracellular Ca2+ and the Type II calcimimetics act only in the presence of Type I calcimimetics. These structurally novel Type II calcimimetics are the first compounds that selectively target the Ca2+ receptor. As such, they may be suitable as drugs or drug leads to treat various bone and mineral disorders, such as hyperparathyroidism, where it is desirable to lower plasma levels of PTH (Silverberg et al., 1997).

Acknowledgements

We thank Dr. Shigetada Nakanishi for providing the SKR clone, Karen Krapcho and Rachel Simin for providing the mGluR1a clone and Sharon Bennett for assistance in preparing the manuscript.

Footnotes

  • Send reprint requests to: Lance Hammerland, Ph.D., NPS Pharmaceuticals, Inc., 420 Chipeta Way, Salt Lake City, UT 84108. E-mail: lhammerland{at}npsp.com

  • Abbreviations:
    PTH
    parathyroid hormone
    BoPCaR
    bovine parathyroid Ca2+ receptor
    hPCaR
    human parathyroid Ca2+ receptor
    SKR
    substance K receptor
    mGluR
    metabotropic glutamate receptor
    MBS
    modified Barth’s solution
    HEPES
    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
    ICl
    chloride current
    • Received November 6, 1997.
    • Accepted February 13, 1998.

References

  1. ↵
    1. Turner AJ,
    2. Bachelard HS
    1. Barnard EA,
    2. Bilbe G
    (1987) Functional expression in the Xenopus oocyte of mRNAs for receptors and ion channels. in Neurochemistry: A Practical Approach, eds Turner AJ, Bachelard HS (ICL Press, Oxford, Washington, DC), pp 243–270.
  2. ↵
    1. Brown EM
    (1991) Extracellular Ca2+ sensing, regulation of parathyroid cell function and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 71:371–411.
    OpenUrlFREE Full Text
  3. ↵
    1. Brown EM,
    2. Butters R,
    3. Katz C,
    4. Kifor O
    (1991a) Neomycin mimics the effects of high extracellular calcium concentrations on parathyroid function in dispersed bovine parathyroid cells. Endocrinology 128:3047–3054.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Brown EM,
    2. Gamba G,
    3. Riccardi D,
    4. Lombardi M,
    5. Butters R,
    6. Kifor O,
    7. Sun A,
    8. Hediger J.,
    9. Lytton MA,
    10. Hebert SC
    (1993) Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature (Lond) 366:575–580.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Brown EM,
    2. Katz C,
    3. Butters R,
    4. Kifor O
    (1991b) Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells. J Bone Miner Res 6:1217–1225.
    OpenUrlPubMed
  6. ↵
    1. Brown EM,
    2. Pollak M,
    3. Seidman CE,
    4. Seidman JG,
    5. Chou Y-HW,
    6. Riccardi D,
    7. Hebert SC
    (1995) Calcium ion-sensing cell-surface receptors. N Eng J Med 333:234–240.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Feng G,
    2. Hannan F,
    3. Reale V,
    4. Hon YY,
    5. Kousky CT,
    6. Evans PD,
    7. Hall LM
    (1996) Cloning and functional characterization of a novel dopamine receptor from Drosophila melanogaster. J Neurosci 16:3925–3933.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Flor PJ,
    2. Gomeza J,
    3. Tones MA,
    4. Kuhn R,
    5. Pin J-P,
    6. Knopfel T
    (1996) The C-terminal domain of the mGluR1 metabotropic glutamate receptor affects sensitivity to agonists. J Neurochem 67:58–63.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Garrett JE,
    2. Capuano IV,
    3. Hammerland LG,
    4. Hung BCP,
    5. Brown EM,
    6. Hebert SC,
    7. Fuller F,
    8. Nemeth EF
    (1995) Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 270:12919–12925.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Goldin AL
    (1992) Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol 207:266–279.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Hammerland LG,
    2. Garrett JE,
    3. Krapcho KJ,
    4. Simin R,
    5. Capuano IV,
    6. Alasti N,
    7. Nemeth EF,
    8. Fuller FH
    (1996) NPS R-467 activation of chimeric calcium-metabotropic glutamate receptors and a calcium receptor deletion mutant indicates a site of action within the transmembrane of the calcium receptor. J Bone Miner Res 11:P272.
    OpenUrl
  12. ↵
    1. Hammerland LG,
    2. Krapcho KJ,
    3. Alasti N,
    4. Simin R,
    5. Garrett JE,
    6. Capuano IV,
    7. Hung BCP,
    8. Fuller FH
    (1995) Cation binding determinants of the calcium receptor revealed by functional analysis of chimeric receptors and a deletion mutant. J Bone Miner Res 10:70.
    OpenUrl
  13. ↵
    1. Ji H,
    2. Sandberg K,
    3. Catt KJ
    (1991) Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in Xenopus laevis oocytes. Mol Pharmacol 39:120–123.
    OpenUrlAbstract
  14. ↵
    1. Masu M,
    2. Tanabe Y,
    3. Tsuchida K,
    4. Shigemoto R,
    5. Nakanishi S
    (1991) Sequence and expression of a metabotropic glutamate receptor. Nature (Lond) 349:760–765.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Nakanishi S
    (1991) Mammalian tachykinin receptors. Annu Rev Neurosci 14:123–136.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bilezikian JP,
    2. Raisz LG,
    3. Rodan GA
    1. Nemeth EF
    (1996) Calcium receptors as novel drug targets. in Principles of Bone Biology, eds Bilezikian JP, Raisz LG, Rodan GA (Academic Press, San Diego), pp 1019–1035.
  17. ↵
    1. Nemeth EF,
    2. Scarpa A
    (1987) Rapid mobilization of cellular Ca2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor. J Biol Chem 262:5188–5196.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Silverberg SJ,
    2. Bone HG,
    3. Marriott TB,
    4. Locker FG,
    5. Thys-Jacobs S,
    6. Dziem G,
    7. Kaatz S,
    8. Sanguinetti EL,
    9. Bilezikian JP
    (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506–1510.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Steffey ME,
    2. Fox J,
    3. VanWagenen BC,
    4. Delmar EG,
    5. Balandrin MF,
    6. Nemeth EF
    (1993) Calcimimetics: structurally and mechanistically novel compounds that inhibit parathyroid hormone secretion from parathyroid cells. J Bone Miner Res 8:S175.
    OpenUrl
  20. ↵
    1. Stuhmer W
    (1992) Electrophysiological recording from Xenopus oocytes. Methods Enzymol 207:319–339.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Allosteric Activation of the Ca2+ Receptor Expressed in Xenopus laevis Oocytes by NPS 467 or NPS 568

Lance G. Hammerland, James E. Garrett, Benjamin C. P. Hung, Cynthia Levinthal and Edward F. Nemeth
Molecular Pharmacology June 1, 1998, 53 (6) 1083-1088;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement